CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
OPERATING ACTIVITIES:
Net Income (Loss)	$ (2,679,570)	$ (51,183)
Adjustments to reconcile Net loss to Net cash provided by operating activities:
Depreciation and amortization	302,338	350,455
Share-based compensation	13,506	22,237
Amortization of debt issuance costs and discount	9,406	10,755
Deferred income taxes	(8,337)	(3,633)
Change in fair value of contingent consideration	(951)	(6,771)
Loss on extinguishment of debt	0	13,753
Acquired in-process research and development charges	68,700	5,000
Asset impairments	1,951,216	50,393
Debt valuation adjustments	89,197	0
(Gain) loss on sale of business and other assets	(11,760)	198
Other	2,083	0
Changes in assets and liabilities which provided (used) cash:
Accounts receivable	154,645	(23,601)
Inventories	(31,100)	29,729
Prepaid and other assets	72,111	5,508
Accounts payable, accrued expenses and other liabilities	219,668	4,486
Income taxes payable/receivable, net	8,459	53,588
Net cash provided by operating activities	159,611	460,914
INVESTING ACTIVITIES:
Capital expenditures, excluding capitalized interest	(77,865)	(61,496)
Capitalized interest payments	(3,140)	(2,721)
Proceeds from the U.S. Government Agreement	13,601	0
Acquisitions, including in-process research and development, net of cash and restricted cash acquired	(89,520)	(5,000)
Product acquisition costs and license fees	0	(2,486)
Proceeds from sale of business and other assets, net	22,378	1,357
Net cash used in investing activities	(134,546)	(70,346)
FINANCING ACTIVITIES:
Proceeds from issuance of notes, net	0	1,279,978
Proceeds from issuance of term loans, net	0	1,980,000
Repayments of notes	(180,342)	0
Repayments of term loans	(10,000)	(3,305,475)
Adequate protection payments	(168,643)	0
Repayments of other indebtedness	(4,501)	(4,044)
Payments for debt issuance and extinguishment costs	0	(8,574)
Payments for contingent consideration	(1,939)	(3,355)
Payments of tax withholding for restricted shares	(1,898)	(14,688)
Proceeds from exercise of options	0	622
Net cash used in financing activities	(367,323)	(75,536)
Effect of foreign exchange rate	(4,674)	238
NET (DECREASE) INCREASE IN CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS	(346,932)	315,270
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, BEGINNING OF PERIOD	1,631,310	1,385,000
CASH, CASH EQUIVALENTS, RESTRICTED CASH AND RESTRICTED CASH EQUIVALENTS, END OF PERIOD	$ 1,284,378	$ 1,700,270